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Background: Repeated participation is important in faecal immunochemical testing (FIT) screening for colorectal
cancer (CRC). However, a large number of screening invitations over time may lead to screening fatigue and
consequently, decreased participation rates. We evaluated the impact of screening fatigue on overall screening
programme effectiveness.
Methods: Using the ASCCA model, we simulated the Dutch CRC screening programme consisting of biennial FIT
screening in individuals aged 55–75. We studied the resilience of the programme against heterogeneity in screening
attendance and decrease in participation rate due to screening fatigue. Outcomes were reductions in CRC incidence
and mortality compared to no screening.
Results: Assuming a homogenous 63 % participation, i.e., each round each individual was equally likely to attend
screening, 30 years of screening reduced CRC incidence and mortality by 39 and 53 %, respectively, compared to no
screening. When assuming clustered participation, i.e., three subgroups of individuals with a high (95 %), moderate
(65 %) and low (5 %) participation rate, screening was less effective; reductions were 33 % for CRC incidence and 43 %
for CRC mortality. Screening fatigue considerably reduced screening effectiveness; if individuals refrained from
screening after three negative screens, model-predicted incidence reductions decreased to 25 and 18 % under
homogenous and clustered participation, respectively. Figures were 34 and 25 % for mortality reduction.
Conclusions: Screening will substantially decrease CRC incidence and mortality. However, screening effectiveness can
be seriously compromised if screening fatigue occurs. This warrants careful monitoring of individual screening behaviour
and consideration of targeted invitation systems in individuals who have (repeatedly) missed screening rounds.
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Several countries have implemented a colorectal cancer
(CRC) screening programme based on faecal immuno-
chemical testing (FIT) [1]. Due to imperfect sensitivity of
FIT, around 20 % of CRCs and 70 % of advanced aden-
omas are missed in a single screening round [2–5]. To in-
crease the probability of presymptomatic detection of
advanced neoplasia, repeated screening is required. Thus,
participation in multiple screening rounds is essential to* Correspondence: mj.greuter@vumc.nl
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grammes to prevent CRC.
Only three studies have evaluated participation over
multiple rounds of FIT screening [6–8]. These studies
showed varying participation patterns; two Dutch studies
concerning three screening rounds reported that partici-
pation increased in the third round [6, 7] whereas an
Italian study concerning four screening rounds demon-
strated a fluctuating participation pattern [8]. Regarding
repeated participation in these studies, the majority of
invitees participated at least once. More importantly, in
one of the Dutch studies 54 % of invitees participated inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Test characteristics of FIT and colonoscopy
Variable Value Reference
FIT characteristics per lesion Men Women [11, 14]
Specificity 0.96a 0.97a
Sensitivity diminutive adenoma 0.0041 0.003
Sensitivity small adenoma 0.12 0.10
Sensitivity large adenoma 0.30 0.28
Sensitivity CRC early stage 0.50 0.50
Sensitivity CRC late stage 0.85 0.85
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four round participation rate of 38 % [8].
Based on the limited and inconclusive data on partici-
pation, it is uncertain whether invitees of an 11-round
FIT screening programme will stay motivated to attend
screening. Invitees may lose the motivation to participate
because of a false perception of decreased CRC risk
after several negative test outcomes [9]. We denote this
phenomenon by the term ‘screening fatigue’, leading to
decreased participation. Screening fatigue may be a
potential threat for FIT screening programmes since
repeated testing is important to achieve reasonable
sensitivity for advanced neoplasia. Furthermore, CRC
risk increases with age [10] which stresses the impor-
tance of participation among older individuals.
We evaluated the potential impact of screening fatigue
on long-term screening effectiveness in terms of CRC inci-
dence and mortality reductions compared to no screening.
We considered several scenarios differing in participation
pattern, number of negative screens after which screening




The Adenoma and Serrated pathway to Colorectal CAncer
(ASCCA) model, which is extensively described elsewhere,
[11] was used for all analyses. This model simulates indi-
vidual health trajectories from age 20 to age 90 or death,
whichever comes first. During his lifetime, an individual
can develop up to ten adenomas and ten serrated lesions.
The development of each lesion in terms of growth in size
and malignant features, i.e., dysplasia and villosity, is mo-
delled independently. Only advanced adenomas can pro-
gress to CRC. Once a tumour has developed, there is each
year a chance that the tumour becomes detected by symp-
toms, or progresses to a more advanced stage.
For the current evaluation, we assumed that all CRCs
arise from adenomas to allow for comparability of model
results to other CRC models. Thus, serrated lesions are
considered innocuous. The model satisfactorily reproduces
the Dutch sex- and age-specific adenoma prevalence, as
well as Dutch CRC incidence and mortality rates [11].
Screening programme
The model was set up to simulate the Dutch CRC screen-
ing programme consisting of biennial FIT screening. Phased
implementation of this programme has started in 2014.
Each year, more birth cohorts are included until full imple-
mentation in 2019. From that year onwards, all individuals
aged 55 to 75 will be biennially invited. Because data from
the fully implemented programme are not yet available, we
derived the participation rate from a pilot study in which
participation was 63 % [7].A positive test is followed by referral to diagnostic colo-
noscopy. We set adherence to diagnostic colonoscopy at
83 %, as observed in the Dutch screening programme in
2014 [12]. Of note, a Dutch screening implementation trial
reported similar figures for all age groups [6]. During col-
onoscopy, all detected adenomas are completely removed.
Furthermore, we incorporated a small risk of complications
to include both screening benefit and burden. Colonoscopy
surveillance is modelled in accordance with Dutch guide-
lines [13]. That is, a risk score is calculated based on the
findings during colonoscopy. This risk score determines
the surveillance interval, i.e., 3 or 5 years. Similarly to diag-
nostic colonoscopy, participation for surveillance was set at
83 %. Surveillance ends at age 75.
Test characteristics
Table 1 shows test characteristics of FIT and colonoscopy.
FIT sensitivity and specificity were obtained by calibration,
following a previously reported procedure [11]. With these
characteristics we were able to reproduce positivity rates,
detection rates and positive predictive values as reported
in a Dutch FIT screening trial [14]. Detection rates of col-
onoscopy were based on a systematic review on polyp
miss rates [15].
Scenarios
Besides the comparator scenario without screening, we
considered sixty-two screening scenarios differing in par-
ticipation pattern, number of negative screens after which
screening fatigue occurs and decrease in participation rate
due to screening fatigue. We considered two participation
patterns, in order to assess the effect of repeated participa-
tion. In the first pattern, each individual has each round
the same probability, i.e., 63 %, of participating in screen-
ing. Thus, participation in a single round is not correlated
to participation in previous rounds. We refer to this
pattern as homogenous participation.
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tered participation and is based on the observation that
some individuals participate in most screening rounds
whereas others participate only sporadically [7, 8, 16].
Individuals in the model were allocated to a high, mod-
erate or low participation group, in which each group
was assigned a different participation rate, i.e., 95, 65
and 5 % respectively. To determine the percentage of
individuals in each subgroup, the model was calibrated
against data from a Dutch study concerning three
rounds of FIT screening [7]. Calibration targets included
a 63 % overall participation rate per round, the percent-
age of individuals who completed all screening rounds
and the percentage of individuals who participated at
least once. Respectively 45, 25 and 30 % of the popu-
lation were allocated to the high, moderate and low
participation subgroup. We assumed that individuals
remain in the same participation group during the entire
screening programme.
We first simulated two scenarios differing in participa-
tion pattern in which screening fatigue did not occur.
Subsequently, to fully evaluate the potential threat of
screening fatigue, we hypothesized that it could occur
after any specific number x of negative screens, with x
running from one to ten. We did not assume that
negative screens were necessarily consecutive because
individuals do not participate in every round due to
imperfect participation. Furthermore, after onset of
screening fatigue at screen x, we assumed a decrease
in participation of either 25 or 50 % (relative decrease)
or that individuals would refrain from screening. This
resulted in 60 screening scenarios in which screening
fatigue occurred.
Analyses
We modelled screening from 2014 to 2044 while
accounting for phased implementation. We started with
a population based on the 2013 Dutch population
age-composition and assumed that this population
will age in accordance with predictions of the Central
Bureau of Statistics [17]. Outcomes of each strategy
were model-predicted CRC incidence and mortality
per 100,000 individuals per year.
Furthermore, we calculated individual CRC risk after
any number of consecutive negative screens, if the individ-
ual would refrain from further screening. For this purpose,
we simulated a cohort of 20,000,000 individuals assuming
that all individuals are fully compliant with screening.
Screening was ceased after one to eleven screens and indi-
viduals with a positive FIT at any round were excluded.
Outcomes were age-specific CRC incidence and mortality
per 100,000 individuals as well as CRC risk in the
remaining life-time of a 60-, 64-, 68-, 72- and 76-year old
with consecutive negative screens.Since this study focused on evaluation of multiple
behavioural scenarios, detailed sensitivity analysis for any
particular scenario was not performed. Rather, the sensi-




In the scenario without screening, model-predicted age-
standardised CRC incidence and mortality rates were
respectively 77 and 30 per 100,000 individuals in 2014.
Due to population ageing, these rates increased to 109
and 44 per 100,000 individuals, respectively, in 2044.
Thirty years of screening significantly decreased both
CRC incidence and mortality. However, reductions were
dependent on participation pattern. When assuming
homogenous participation, CRC incidence and mortality
rates in 2044 were respectively 67 and 21 per 100,000 in-
dividuals. These rates correspond to a reduction of 39
and 53 % compared to no screening. Screening impact
under clustered participation was lower; CRC incidence
decreased by 33 % whereas CRC mortality decreased by
43 % compared to no screening.
Assuming homogenous participation, individuals par-
ticipated on average in six screening rounds [5th - 90th
percentile: 4–9]. For clustered participation, the average
number of rounds was five. When considering the
different participation groups separately, individuals in
the high, moderate and low participation group attended
on average eight [5th - 95th percentile: 9–11], six [5th -
95th percentile: 4–10] and one [5th - 95th percentile: 0–2]
screening round, respectively. These figures include indi-
viduals who do no longer participate due to a positive test
result and thus, are referred to diagnostic colonoscopy
and surveillance.
Impact of screening fatigue
We evaluated the impact of screening fatigue assuming
both homogenous and clustered participation. Figure 1
shows reductions in CRC incidence and mortality com-
pared to no screening for different scenarios of screening
fatigue assuming homogenous participation. As expected,
screening fatigue had the highest impact on screening ef-
fectiveness when it occurred after the first negative screen
and individuals would no longer participate from that
point, since this minimised total lifetime exposure to
screening. In that case, screening effectiveness decreased
from a 39 % (no screening fatigue) to an 8 % reduction in
CRC incidence and from a 53 % (no screening fatigue) to
a 13 % reduction in CRC mortality.
In the situation where screening fatigue did not occur
before six negative screens, and the decrease in participa-
tion was limited to 25 %, the long-term impact of scree-
ning was not substantially affected. However, if screening
Fig. 1 Reduction in CRC incidence (a) and mortality (b) assuming homogenous participation and reduction in CRC incidence (c) and mortality (d)
assuming clustered participation after thirty years of population-based screening compared to no screening for different scenarios of screening fatigue
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larly if participation in subsequent rounds decreased by
50 % or even 100 %, the long-term impact of screening
was more substantially attenuated. For example, if individ-
uals refrained from further screening after three negativescreens, reductions in CRC incidence and mortality were
respectively 25 and 34 %.
Figure 1 shows reductions in CRC incidence and mor-
tality compared to no screening, assuming clustered par-
ticipation. The observed pattern was roughly similar as for
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fatigue seems to be slightly more pronounced. For ex-
ample, if individuals refrained from further screening after
three negative screens, reductions in CRC incidence and
mortality were respectively 18 and 25 %.
CRC risk after consecutive negative screens
Figure 2 shows age-specific CRC incidence and mortality
in individuals who had one to eleven consecutive negative
screens as well as in never-screened individuals. Indivi-
duals with one or more negative screens had a lower CRC
risk than never-screened individuals. For example, model-
predicted CRC incidence at age 75 was 334/100,000 in
never-screened individuals. The incidence decreased to
284/100,000 in individuals who had one negative screen at
age 55 years and to 34/100,000 in individuals who had
eleven negative screens between age 55–75. Each ad-
ditional negative screen decreased CRC risk, except for
the eleventh negative screen; CRC incidence was compar-
able in individuals who had ten or eleven negative screens.
For CRC mortality, a similar pattern was observed.
Table 2 shows CRC risk in the remaining lifetime of a
60- to 76-year old individual after one to eleven con-
secutive negative screens. In never-screened individuals,Fig. 2 Age-specific CRC incidence (a) and mortality (b) after one to eleventhe predicted lifetime risk varied between 6.3 % for a 60-
year old to 4.4 % for a 76-year old. Each negative screen
lowered the lifetime risk, except for the eleventh nega-
tive screen.
Discussion
This study assessed the impact of screening fatigue
on long-term screening effectiveness. When assuming
homogenous participation, 30 years of screening led to a
39 and 53 % model-predicted reduction in respectively
CRC incidence and mortality. Screening was less effective
when assuming clustered participation; reductions were
33 and 43 %. Screening fatigue considerably reduced
screening effectiveness. If individuals refrained from fur-
ther screening after three negative screens, reductions in
CRC incidence were decreased to 25 and 18 % under
homogenous and clustered participation, respectively.
Figures were 34 and 25 % for mortality reduction.
In all scenarios, screening effectiveness was lower as-
suming clustered participation compared to homogenous
participation. This holds for screening in general. How-
ever, the extent of the difference in screening effectiveness
is dependent on the particular clustering pattern. Since we
based our assumptions for clustering on a Dutch studyconsecutive negative screens
Table 2 Risk of CRC in the remaining lifetime of a 60-, 64-, 68-,
















0a 6.3 6.0 5.6 5.1 4.4
1 5.2 5.2 5.0 4.6 4.1
2 4.7 4.7 4.6 4.3 3.9
3 3.9 4.2 4.2 4.0 3.6
4 b 3.7 3.7 3.6 3.3
5 b 3.0 3.3 3.2 3.0
6 b b 2.8 2.8 2.7
7 b b 2.2 2.4 2.4
8 b b b 2.0 2.0
9 b b b 1.5 1.7
10 b b b b 1.3
11 b b b b 1.3
aNo screening scenario
bWe assumed the individual would refrain from further screening
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will affect the difference in screening effectiveness.
In clustered participation, which is probably closer to
reality than homogenous participation, more individ-
uals are subjected to multiple screening rounds whereas
in homogenous participation, more individuals are sub-
jected to at least one screening round. This suggests that
efforts to increase participation in non-attendees may be
more beneficial to enhance screening effectiveness than
attempts to increase repeated participation. Studies evalu-
ating participation over multiple rounds of FIT screening
have shown that the group of non-attendees is consider-
able; in two screening rounds, 25 to 35 % of invitees will
not participate [7, 16] and this is still around 25 % in three
or four screening rounds [7, 8]. Participation can be in-
creased by, for example, advance notification letters and
reminders [18].
Assumptions about participation behaviour vary widely
among CRC screening models. For example, the SimCRC
model assumes that 10 % of individuals are never screened,
whereas the remaining 90 % are equally divided among a
low, moderate and high participation group [19]. The MIS-
CAN model also assumes that 10 % of individuals are non-
attendees but does not allocate individuals to subgroups
differing in participation. However, they incorporated cor-
related participation by assuming that 80 % of individuals
that participated in a certain round will also participate in
the next round [20]. These differences in assumptions will
lead to differences in model predictions. To improve the
accuracy of model-based predictions of screening impact,access to data on individual screening behaviour is ex-
tremely valuable.
For homogenous and clustered participation, long-term
screening effectiveness was hardly affected by screening fa-
tigue when it occurred after respectively seven or nine
negative screens. This is due to the fact that few individuals
reach that number of negative screens. Under homogenous
participation, each individual had a 63 % chance to partici-
pate in screening every 2 years. Of the participating indi-
viduals, around 6 % has a positive FIT [21]. Furthermore,
individuals in the screening eligible age range are at risk of
dying of other causes then CRC. Consequently, few indi-
viduals reach seven or more negative screens. Under clus-
tered participation, slightly more individuals will reach a
high number of negative screens due to the 95 % participa-
tion rate in the high participation group (45 % of popula-
tion). Therefore, the potential impact of screening fatigue
is higher assuming clustered participation. Note that this
does not imply that FIT screening programmes could actu-
ally be halted earlier, that is, after seven (homogenous
participation) or nine (clustered participation) screening
rounds. It is due to imperfect participation that as many as
eleven rounds should be offered to achieve on average six
(homogenous participation) or five (clustered participation)
rounds. Moreover, our analyses of CRC risk in the
remaining lifetime after one to ten negative screens showed
that for an individual, every additional negative screen led
to a further decrease in CRC risk. Note that even after
eleven negative screens, CRC risk is still non-negligible.
In this study, we have focused on the effectiveness of
continued screening in individuals with multiple negative
screening tests. Another viewpoint that could be taken is
that of the cost-effectiveness of continuing to offer biennial
screening in individuals with multiple negative screens; this
may not be a cost-effective strategy. In cervical cancer
screening, studies have reported that several consecutive
negative tests imply reduced risk [22–25]. This has led, in
some settings, to current guidelines for less frequent
screening after multiple negative cervical cancer screening
tests, [26–28] although this is not a usual feature of most
screening programmes. It is possible that less frequent
CRC screening may in the future be justified in individuals
with multiple consecutive negative tests, but a compre-
hensive evidence base including observational data from
screening programmes would be required on the long-
term protective effects, in order to support such a recom-
mendation. Further cost-effectiveness research, grounded
in such evidence, would also be required. On the other
hand, such an individualized screening strategy is complex
to organize. Moreover, with respect to FIT screening, there
are still important issues to address first such as optimizing
currently suboptimal participation rates.
Three studies have investigated participation in FIT
screening in multiple screening rounds [6–8]. It is
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studies to a full programme consisting of eleven screening
rounds because results are inconsistent and the number of
rounds studied is still limited. For example, Stegeman
et al. [6] reported a slight increase in participation rate in
the third round. This increase was more pronounced in a
comparable Dutch study [7]. In contrast, participation
rates in an Italian study evaluating four rounds were
fluctuating; participation was around 56 % in the first
and third round and around 62 % in the second and
fourth round [8].
Data on participation in more than four FIT screening
rounds is not available. Also individual participation pat-
terns are not reported. Participation is likely to be
setting-specific and depends on several factors including
the organisation of screening and associated communi-
cation and health promotion activities. Therefore, it is
still unknown if screening fatigue will occur in a particular
setting. We showed that screening fatigue can have a con-
siderable impact on screening effectiveness. This warrants
careful monitoring of individual participation behaviour in
FIT screening.
In a programme consisting of only a few screening
rounds, the probability that screening fatigue will occur is
likely to be small. Therefore, the use of a highly sensitive
screening test is important because this enables elongation
of the screening interval. For example, in colonoscopy
screening, the interval between subsequent rounds can be
safely extended to 10 years [29] and only a small number
of screening rounds in a lifetime is required.
Our study has several limitations. Firstly, individuals
with an increased CRC risk, e.g., men and low SES indi-
viduals, [30–32] might be more prone to screening fatigue
since they are already less likely to participate in screening
[33]. We did not take this into account.
Furthermore, we assumed that screening fatigue would
occur after the same number of negative screens in all in-
dividuals whereas it is more likely that this will differ be-
tween individuals. However, this variation is implicitly
included in the scenarios where we assumed a decrease in
participation due to screening fatigue; individuals still have
a chance of participating in subsequent screening rounds.
We also did not differentiate between individuals who
had x consecutive negative tests and individuals who had
x negative tests with a longer time-period in between. We
believe this would not have substantially affected our re-
sults, because there is considerable variation in individual
participation patterns due to imperfect compliance.
On the other hand, we simulated a realistic screening
programme, assuming participation rates based on
screening pilots and accounting for phased implementa-
tion. Furthermore, we evaluated numerous strategies
differing in participation pattern, number of negative
screens after which screening fatigue occurs and decreasein participation rate due to screening fatigue, in order to
comprehensively evaluate the potential impact of screen-
ing fatigue.
Conclusion
Screening will considerably decrease CRC incidence and
mortality. However, the effectiveness of a FIT screening
programme can be seriously compromised if screening
fatigue occurs. This warrants careful monitoring of indi-
vidual screening behaviour and consideration of targeted
invitation and reminder systems for screening in individ-
uals who have (repeatedly) missed screening rounds.
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